At the annual meeting of the Association for Accessible Medicines (Access 2023), Shark Tank’s Mark Cuban explained his dedication to and the inner workings of his online pharmacy that provides generic drugs to patients for significantly lower prices than traditional pharmacies.
At the annual meeting of the Association for Accessible Medicines (Access 2023), billionaire investor Mark Cuban detailed why he chose to develop an online pharmacy that specializes in low-cost medicines and acts as a disruptor to big pharmaceutical wholesale manufacturers.
Cuban is best known as an investor on ABC’s Shark Tank as well as the owner of the Dallas Mavericks. He started his career as an entrepreneur by creating MicroSolutions, a computer consulting service, which he sold in 1990 for $6 million. He announced the launch of his online pharmacy in January 2022.
The pharmacy, known as the Mark Cuban CostPlus Drug Company, is the only one of Cuban’s companies that he has directly attached his name to, which he said shows his determination and commitment to its mission.
“I've never put my name on any other company. And I thought it was important because we were coming out of nowhere. I wanted people to know I was committed to it financially, emotionally, intellectually, and I also wanted patients to know they can trust it—that I wouldn't put my name on it unless I was fully behind it.”
Although Cuban is worth an estimated $4.8 billion, he’s seen firsthand how price gauging on prescription drugs has affected people, sharing the story of a friend who became paralyzed, lost his insurance, and was charged $30,000 for a 3-month supply of draxidopa (Northera). Cuban said that in cases like this and with high-cost biologics, CostPlus is working with manufacturers and talking to them about federal- and state-supported payment programs.
So far, CostPlus only carries generic medications. However, Cuban said that he hasn’t ruled out adding biosimilars to the mix someday.
“We've stopped looking at it from the manufacturers’ perspective, because if you're able to increase the Rx fill rate, you mitigate the risk, which means you can charge less….If we can put together programs that increase that fill rate, not to make more money, patients will pay less, the cost to [companies] will be less, and everybody will benefit. That's where we hope to be on the expensive biologics. And will we get there tomorrow? No, but we'll get there.”
The company functions by working with nontraditional pharmacy benefit managers (PBMs). When a PBM signs up to work with CostPlus, it’s not allowed to do rebates or spread pricing, where a PBM will charge payers more for a prescription than what it will reimburse the pharmacy. Because of this promise, CostPlus is able to foster relationships between manufacturing companies and its partner PBMs.
Cuban said that a main focus of the pharmacy is to expand patient access to medicines, especially during times of nationwide struggle, such as the rise in inflation rates and drug supply shortages. Additionally, he seeks to increase price transparency and trust in the supply chain.
The website for CostPlus aims to make it easy for patients to sign up and contact providers about switching pharmacies. Patients can receive their medications in the mail and can directly see the list prices of the branded drugs and how much they save by switching to the listed generic. Cuban said that the company has not spent any money on advertising because word of mouth is valuable enough.
“We haven't spent a nickel on advertising, and we won't….Imagine if you need a medicine, you're telling everybody. You're telling your doctor, you're on online forums, you're speaking to everybody that you know that has the same ailment that you have. That's our marketing.”
When asked about why sometimes patients’ filled medications come in different colors or packaging, Cuban said that it was because manufacturers could change over time. However, he noted that feedback has shown that the change in generics has not posed an issue, which he attributed to CostPlus’ commitment to instilling trust with its patients.
Cuban explained that CostPlus’ biggest barriers are being new and companies being scared to work with PBMs.
“It took some time for people to think, ‘OK, it's just the Shark Tank guy. He's just messing around with this.’ And now, people are starting to realize we're real. Hopefully, by the end of this week, we'll have 2 million accounts set up….So, we're just going to keep on seeing where it takes us. I have this saying, when you run with the elephants, there's the quick and the dead. And so, we have to be quick. I don't think we've impacted anybody else's business in a big way, but we'll get there.”
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.